BACKGROUND: The brain-derived neurotrophic factor (BDNF) gene is a candidate gene in therapeutic responses to antidepressants. The aim of the study was to determine the effects of BDNF allelic variability on responses to escitalopram treatment at 3 weeks after treatment initiation and at a 6-week endpoint. METHODS: We included 187 Caucasian subjects with depression; 153 completed the 6-week study. Clinical evaluation was performed using the Montgomery and Asberg Depression Rating Scale (MADRS) before and after 3-6 weeks of treatment. RESULTS: After 3 weeks of treatment, we saw significantly better treatment responses in the Met carriers and greater antidepressant resistance among the Val/Val homozygotes. Relative to Val/Val homozygous (59.78 %), a significantly greater proportion of subjects Met-carriers (77.94 %) responded to escitalopram treatment (χ (2) = 5.88, p = 0.015). After 6 weeks, we found the same pattern of results but this effect did not reach statistical significance (χ (2) = 2.07, p = 0.15). CONCLUSION: These findings highlight a significant association between the BDNF valine to methionine substitution (Val(66)Met) polymorphism and the treatment response to escitalopram in a Caucasian population of severely depressed inpatients.
BACKGROUND: The brain-derived neurotrophic factor (BDNF) gene is a candidate gene in therapeutic responses to antidepressants. The aim of the study was to determine the effects of BDNF allelic variability on responses to escitalopram treatment at 3 weeks after treatment initiation and at a 6-week endpoint. METHODS: We included 187 Caucasian subjects with depression; 153 completed the 6-week study. Clinical evaluation was performed using the Montgomery and Asberg Depression Rating Scale (MADRS) before and after 3-6 weeks of treatment. RESULTS: After 3 weeks of treatment, we saw significantly better treatment responses in the Met carriers and greater antidepressant resistance among the Val/Val homozygotes. Relative to Val/Val homozygous (59.78 %), a significantly greater proportion of subjects Met-carriers (77.94 %) responded to escitalopram treatment (χ (2) = 5.88, p = 0.015). After 6 weeks, we found the same pattern of results but this effect did not reach statistical significance (χ (2) = 2.07, p = 0.15). CONCLUSION: These findings highlight a significant association between the BDNFvaline to methionine substitution (Val(66)Met) polymorphism and the treatment response to escitalopram in a Caucasian population of severely depressed inpatients.
Authors: George S Alexopoulos; Charles E Glatt; Matthew J Hoptman; Dora Kanellopoulos; Christopher F Murphy; Robert E Kelly; Sarah S Morimoto; Kelvin O Lim; Faith M Gunning Journal: J Affect Disord Date: 2010-03-25 Impact factor: 4.839
Authors: Xiang Yang Zhang; Jun Liang; Da Chun Chen; Mei Hong Xiu; Fu De Yang; Therese A Kosten; Thomas R Kosten Journal: Psychopharmacology (Berl) Date: 2012-01-26 Impact factor: 4.530
Authors: D Munno; S Sterpone; S Fania; F Cappellin; G Mengozzi; M Saroldi; E Bechon; G Zullo Journal: Panminerva Med Date: 2013-12 Impact factor: 5.197
Authors: Michael F Egan; Masami Kojima; Joseph H Callicott; Terry E Goldberg; Bhaskar S Kolachana; Alessandro Bertolino; Eugene Zaitsev; Bert Gold; David Goldman; Michael Dean; Bai Lu; Daniel R Weinberger Journal: Cell Date: 2003-01-24 Impact factor: 41.582
Authors: Annamaria Cattaneo; Massimo Gennarelli; Rudolf Uher; Gerome Breen; Anne Farmer; Katherine J Aitchison; Ian W Craig; Christoph Anacker; Patricia A Zunsztain; Peter McGuffin; Carmine M Pariante Journal: Neuropsychopharmacology Date: 2012-09-19 Impact factor: 7.853
Authors: Mark J Niciu; Nicolas D Iadarola; Dipavo Banerjee; David A Luckenbaugh; Minkyung Park; Marc Lener; Lawrence Park; Dawn F Ionescu; Elizabeth D Ballard; Nancy E Brutsche; Nirmala Akula; Francis J McMahon; Rodrigo Machado-Vieira; Allison C Nugent; Carlos A Zarate Journal: J Psychopharmacol Date: 2017-10-17 Impact factor: 4.153